An assessment of 100 patients at a NHS center in the UK has shown reserve funds in constant would mind costs with the utilization of Granulox, a hemoglobin shower that ties oxygen from the climate and diffuses it into the injury to advance quicker mending.
Pressure Ulcers Drugs Development Market, leg ulcers, diabetic foot ulcers, burns, and wounds from surgery and trauma were among these wounds.
At eight weeks, a break-even analysis of the clinical results showed that enough money was saved on dressings to pay for Granulox treatment. At 26 weeks, patients saved an average of £82 on dressings, and Granulox treatment cost an average of £140, compared to £221 for patients in the control group.
Ninety percent of Granulox-treated wounds had healed by 20 weeks, whereas half of the patients in the control group had not healed after six months.
Dr. Duncan Stang, the national diabetes foot coordinator for Scotland, stated: Non-healing wounds can have a devastating effect on a patient’s quality of life. An invaluable opportunity exists to assist these patients without burdening the NHS financially and, in fact, to demonstrate cost savings.
“The analysis does demonstrate cost-effectiveness, which is excellent.” “What is also really interesting about this work is the reduced healing times, which benefit patients and of course healthcare teams working in an ever-stretching NHS, especially in wound care.” “The analysis does demonstrate cost-effectiveness.”
